REFERENCES
- Berdel W. (1991) Br. J. Cancer, 64, 208–211.
- Berger M., Sobottka S., Konstantinov S.M., Eibl H. (1998) Drugs Today, 34, 73–81.
- Dineva I., Zaharieva M., Konstantinov S., Eibl H., Berger M.R. (2012) J. Cancer Res. Clin. Oncol., 138, 1909–1917.
- Fish S., Ruoslaht E. (1997) Curr. Opin. Cell Biol., 9, 7001–7006.
- Geilen C., Haase R., Buchner K., Wieder T., Hucho F., Reutter W. (1991) Eur. J. Cancer, 27, 1650–1653.
- Hilgard P., Klenner T., Engel J. (1999) Drug News Perspect., 12, 69–72.
- Jendrossek V., Erdlenbruch B., Hunold A., Kugler W., et al.. (1999) Int. J. Oncol., 14, 15–22.
- Jiang P., Enomoto A., Takahashi M. (2009) Cancer Lett., 284, 122–130.
- Konstantinov S., Eibl H., Berger M.R. (1999) Br. J. Haematol., 107, 365–374.
- Konstantinov S., Topashka-Ancheva M., Benner A., Berger M.R. (1998) Int. J. Cancer, 77, 778–786.
- Langen P., Maurer H.R., Brachwitz H., Eckert K., Veit A., Vollgraf C. (1992) Anticancer Res., 12, 2109–2112.
- Muschiol C., Berger M.R., Schuler B., Scherf H.R., et al.. (1987) Lipids, 22, 930–934.
- Pehlivanova V., Tsoneva I., Tzoneva R. (2012) Cancer Cell Int., 12, 9.
- Unger C., Sindermann H., Peukert M., Hilgard P., Engel J., Eibl H. (1992) Prog. Exp. Tumor Res., 34, 153–159.
- Yosifov D., Todorov P., Zaharieva M., Georgiev K., et al.. (2011) Cancer Chemother. Pharmacol., 67, 13–25.